Advances in the pathogenesis of FLT3 -mutated acute myeloid leukemia and targeted treatments.
Travaglini S, Gurnari C, Ottone T, Voso MT., Free PMC Article

Inhibition of NOTCH4 sensitizes FLT3/ITD acute myeloid leukemia cells to FLT3 tyrosine kinase inhibition.
Zhu R, Shirley CM, Chu SH, Li L, Nguyen BH, Seo J, Wu M, Seale T, Duffield AS, Staudt LM, Levis M, Hu Y, Small D.

FLT3-ITD regulation of the endoplasmic reticulum functions in acute myeloid leukemia.
Turos-Cabal M, Sánchez-Sánchez AM, Puente-Moncada N, Herrera F, Antolin I, Rodríguez C, Martín V.

Clinico-Radio-Pathologic Correlation of Leukostasis in Acute Myeloid Leukemia with FLT3 Mutation.
Bello E, Liao H, Patel SA.

High FLT3 expression increases immune-cell infiltration in the tumor microenvironment and correlates with prolonged disease-free survival in patients with non-small cell lung cancer.
Kuncman Ł, Orzechowska M, Milecki T, Kucharz J, Fijuth J., Free PMC Article

Current knowledge about FLT3 gene mutations, exploring the isoforms, and protein importance in AML.
Macečková D, Vaňková L, Holubová M, Jindra P, Klieber R, Jandová E, Pitule P.

Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency.
Flynn PA, Long MD, Kosaka Y, Long N, Mulkey JS, Coy JL, Agarwal A, Lind EF., Free PMC Article

Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia.
Gutierrez-Camino A, Richer C, Ouimet M, Fuchs C, Langlois S, Khater F, Caron M, Beaulieu P, St-Onge P, Bataille AR, Sinnett D., Free PMC Article

Clinical features and prognostic significance of DNMT3A, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients.
Chen M, Zeng Z, Li X, Qin W, Cai X, Chen S, Lu X.

Insight and Recommendations for Fragile X-Premutation-Associated Conditions from the Fifth International Conference on FMR1 Premutation.
Tassone F, Protic D, Allen EG, Archibald AD, Baud A, Brown TW, Budimirovic DB, Cohen J, Dufour B, Eiges R, Elvassore N, Gabis LV, Grudzien SJ, Hall DA, Hessl D, Hogan A, Hunter JE, Jin P, Jiraanont P, Klusek J, Kooy RF, Kraan CM, Laterza C, Lee A, Lipworth K, Losh M, Loesch D, Lozano R, Mailick MR, Manolopoulos A, Martinez-Cerdeno V, McLennan Y, Miller RM, Montanaro FAM, Mosconi MW, Potter SN, Raspa M, Rivera SM, Shelly K, Todd PK, Tutak K, Wang JY, Wheeler A, Winarni TI, Zafarullah M, Hagerman RJ., Free PMC Article

A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo.
Giannakopoulou E, Lehander M, Virding Culleton S, Yang W, Li Y, Karpanen T, Yoshizato T, Rustad EH, Nielsen MM, Bollineni RC, Tran TT, Delic-Sarac M, Gjerdingen TJ, Douvlataniotis K, Laos M, Ali M, Hillen A, Mazzi S, Chin DWL, Mehta A, Holm JS, Bentzen AK, Bill M, Griffioen M, Gedde-Dahl T, Lehmann S, Jacobsen SEW, Woll PS, Olweus J., Free PMC Article

Functional characterization and response to FLT3 inhibitors in acute myeloid leukaemia with a non-canonical FLT3 mutation: A proof of concept.
Travaglini S, Gurnari C, Antonelli S, Marchesi F, De Angelis G, Ottone T, Divona M, Cristiano A, Hajrullaj H, Mengarelli A, Voso MT.

Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia.
Parvin S, Aryal A, Yin S, Fell GG, Davids MS, Wu CJ, Letai A., Free PMC Article

Prognostic value of the mutation types and dynamics of FLT3-ITD in acute myeloid leukemia.
Koo M, Song IC, Kim J, Kwon GC, Kim SY.

Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy.
Ge SS, Qiu QC, Dai HP, Shen XD, Wu TM, Du JH, Wan CL, Shen HJ, Wu DP, Xue SL, Liu SB.

C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant Leukemia.
Sabatier M, Birsen R, Lauture L, Mouche S, Angelino P, Dehairs J, Goupille L, Boussaid I, Heiblig M, Boet E, Sahal A, Saland E, Santos JC, Armengol M, Fernández-Serrano M, Farge T, Cognet G, Simonetta F, Pignon C, Graffeuil A, Mazzotti C, Avet-Loiseau H, Delos O, Bertrand-Michel J, Chedru A, Dembitz V, Gallipoli P, Anstee NS, Loo S, Wei AH, Carroll M, Goubard A, Castellano R, Collette Y, Vergez F, Mansat-De Mas V, Bertoli S, Tavitian S, Picard M, Récher C, Bourges-Abella N, Granat F, Kosmider O, Sujobert P, Colsch B, Joffre C, Stuani L, Swinnen JV, Guillou H, Roué G, Hakim N, Dejean AS, Tsantoulis P, Larrue C, Bouscary D, Tamburini J, Sarry JE.

NUP98::Nsd1 and FLT3-ITD collaborate to generate acute myeloid leukemia.
Matsukawa T, Yin M, Nigam N, Negi V, Li L, Small D, Zhu YJ, Walker RL, Meltzer PS, Aplan PD., Free PMC Article

[Research Progress of FLT3 Mutation in Acute Myeloid Leukemia --Review].
Guo L, Xiong HX.

RUNX1/ETO regulates reactive oxygen species (ROS) levels in t(8,21) acute myeloid leukaemia via FLT3 and RAC1.
Azlan A, Khor KZ, Rajasegaran Y, Rosli AA, Said MSM, Yusoff NM, Moses EJ.

Disrupting autophagy in FLT3-mutant acute myeloid leukemia.
Grant S., Free PMC Article

Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy.
Zhang W, Yu G, Zhang H, Basyal M, Ly C, Yuan B, Ruvolo V, Piya S, Bhattacharya S, Zhang Q, Borthakur G, Battula V, Konopleva M, Rice WG, Andreeff M., Free PMC Article

Revisiting the prognostic role of FLT3 mutations in acute myelogenous leukemia.
Reikvam H.

FLT3ITD drives context-specific changes in cell identity and variable interferon dependence during AML initiation.
Li Y, Yang W, Patel RM, Casey EB, Denby E, Mendoza-Castrejon J, Rodriguez-Lopez P, Magee JA., Free PMC Article

DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.
Dillon LW, Gui G, Page KM, Ravindra N, Wong ZC, Andrew G, Mukherjee D, Zeger SL, El Chaer F, Spellman S, Howard A, Chen K, Auletta J, Devine SM, Jimenez Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Weisdorf DJ, Hourigan CS., Free PMC Article

Discovery of oxindole-based FLT3 inhibitors as a promising therapeutic lead for acute myeloid leukemia carrying the oncogenic ITD mutation.
Bender O, Shoman ME, Ali TFS, Dogan R, Celik I, Mollica A, Hamed MIA, Aly OM, Alamri A, Alanazi J, Ahemad N, Gan SH, Malik JA, Anwar S, Atalay A, Beshr EAM.